MYGN

QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications

Retrieved on: 
星期四, 五月 30, 2024
NGS, Partnership, Patient, DNA, CDX, PMDA, Ovarian cancer, Myriad Genetics, QGEN, Clinical trial, MYGN, BRCA2, FDA, Neoplasm, Senior, Research, PMA, GIS, Cancer, Genetics, IP, Biomarker, BRCA1, QIAGEN, Innovation, AstraZeneca, HRD

Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved MyChoice CDx® biomarkers

Key Points: 
  • Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved MyChoice CDx® biomarkers
    VENLO, The Netherlands and SALT LAKE CITY, May 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status.
  • The project builds on the recently announced master collaboration agreement between the two companies.
  • “Our partnership with Myriad Genetics underscores a shared commitment to advancing cancer diagnostics.
  • The combined regulatory expertise of QIAGEN and Myriad enables seamless compliance and integration in clinical and companion diagnostic applications.

QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications

Retrieved on: 
星期四, 五月 30, 2024
NGS, Partnership, Patient, DNA, CDX, PMDA, Ovarian cancer, Myriad Genetics, QGEN, Clinical trial, MYGN, BRCA2, FDA, Neoplasm, LOH, Senior, Research, PMA, GIS, Cancer, Genetics, IP, BRCA1, QIAGEN, Innovation, AstraZeneca, HRD

Venlo, the Netherlands, and Salt Lake City, Utah, May 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status.

Key Points: 
  • Venlo, the Netherlands, and Salt Lake City, Utah, May 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status.
  • “Our partnership with Myriad Genetics underscores a shared commitment to advancing cancer diagnostics.
  • The IP license grants QIAGEN the capability to collaborate with pharmaceutical partners to create an IVD-validated test, intended for use as a companion diagnostic outside of the United States.
  • The combined regulatory expertise of QIAGEN and Myriad enables seamless compliance and integration in clinical and companion diagnostic applications.

Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting

Retrieved on: 
星期四, 五月 23, 2024
MCRR, Genetic testing, MYGN, Breast cancer, MRD, Triple-negative breast cancer, Cancer, Genetics, Medicine, Risk assessment

SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies at the 2024 ASCO Annual Meeting.

Key Points: 
  • SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies at the 2024 ASCO Annual Meeting.
  • At booth 25014, Myriad will highlight the value of genetic testing and genomic insights in guiding personalized cancer treatment decisions, as well as share information about upcoming product innovations including MRD and liquid biopsy testing.
  • Description: This study demonstrates that Myriad’s RiskScore improves upon clinical factors for the prediction of triple-negative breast cancer and early onset (
  • “As we continue to innovate and grow our oncology business, our vision remains centered around advancing oncology care for all patients,” said Dr. Daneker.

New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer

Retrieved on: 
星期四, 五月 16, 2024
Patient, Cohort (statistics), Doctor of Philosophy, University, Weight gain, Genetic testing, Myriad Genetics, Risk, JCO, MYGN, Male, Huntsman Cancer Institute, Conference, CCR, MD, ADT, Death, Prostate cancer, Genetics, ASCO, Medicine, Poster, Society, RT, Metastasis

SALT LAKE CITY, May 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that JCO Precision Oncology has published a study showing a clinical cell-cycle risk (CCR) score can accurately predict the benefit of adding androgen deprivation therapy (ADT) to radiation therapy (RT) in men with localized prostate cancer.

Key Points: 
  • (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that JCO Precision Oncology has published a study showing a clinical cell-cycle risk (CCR) score can accurately predict the benefit of adding androgen deprivation therapy (ADT) to radiation therapy (RT) in men with localized prostate cancer.
  • Guidelines currently recommend adding ADT to RT in certain patients with localized prostate cancer.
  • However, patients with a Prolaris CCR score above the multimodal threshold can reduce risk of metastasis by 8.19% on average by adding ADT to RT.
  • In consultation with their providers, many of these men may elect to forgo ADT based on the information in their Prolaris reports.”

Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business

Retrieved on: 
星期二, 五月 7, 2024
Prostate, MYGN, LDT, Myriad Genetics, Breast, Genetic testing, Genetics, Cancer, Patient, Myriad, Laboratory developed test, Medicine

As part of the reorganization, Myriad signed a definitive agreement to sell its EndoPredict® business to Eurobio Scientific, a leading French group in in vitro medical diagnostics and life sciences.

Key Points: 
  • As part of the reorganization, Myriad signed a definitive agreement to sell its EndoPredict® business to Eurobio Scientific, a leading French group in in vitro medical diagnostics and life sciences.
  • Myriad will also license Eurobio the right to sell Prolaris in vitro diagnostic kits outside the U.S.
  • “The change in our international strategy is part of our continued effort to accelerate profitable growth while supporting our biopharma partners in the most efficient manner,” said Paul J. Diaz, president and CEO of Myriad Genetics.
  • “By divesting the EndoPredict business to Eurobio, we believe EndoPredict and our European teammates will have more opportunities to grow given Eurobio’s strength and presence in the European market.

Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor

Retrieved on: 
星期三, 四月 17, 2024
Myriad Genetics, MYGN, Depression, Life, Genetic testing, Mental health, Patient, Medicine, Anxiety, Nursing

When able to attend important events, 71% of the respondents say their mental health has kept them from being fully present. Nearly eight in 10 respondents (78%) said poor mental health prevented them from “having fun/enjoying myself” in the past year -- a number that jumps to 82% for those diagnosed with anxiety and/or depression.

Key Points: 
  • SALT LAKE CITY, April 17, 2024 (GLOBE NEWSWIRE) -- An astonishing 44% of Americans feel they have lost time in their lives due to poor mental health.
  • Of those diagnosed with anxiety and/or depression, half (50%) said they have lost years of their lifetime because of poor mental health – and 12% said they’ve lost decades.
  • When able to attend important events, 71% of the respondents say their mental health has kept them from being fully present.
  • “I had to call off my wedding to focus on my mental health,” said Courtney Nugent, a GeneSight patient based in Massachusetts.

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen

Retrieved on: 
星期二, 四月 16, 2024
Patient, DiGeorge syndrome, American College, MYGN, Pregnancy, Test management, Myriad Genetics, Ventricular septal defect, FACMG, MD, Doctor of Philosophy, Genetic testing, Medical genetics, Genetics, DNA, SNP, PPV, Genomics, Medicine, FACOG, Dietary supplement

“This is now the second publication—one from Myriad and another from a separate laboratory5—showing exemplary PPV for whole-genome-sequencing-based pcfDNA screening.

Key Points: 
  • “This is now the second publication—one from Myriad and another from a separate laboratory5—showing exemplary PPV for whole-genome-sequencing-based pcfDNA screening.
  • This study enables greater confidence for providers when they receive positive screening results for 22q11.2 microdeletion.
  • 22q11.2 deletion syndrome (22q11.2DS), often called DiGeorge syndrome, is caused by deletions on chromosome 22 (22q11.2 microdeletions).
  • The American College of Medical Genetics and Genomics recently recommended that 22q11.2DS screening be offered to all pregnant patients.

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

Retrieved on: 
星期二, 四月 9, 2024
MYGN, Genetics, Overalls, Medicine, Patient, Myriad Genetics, Cohort (statistics), Genetic testing, DSM-IV codes, Pharmaceutical industry

(NASDAQ: MYGN), a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study of nearly 21,000 patients that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight® Psychotropic test .

Key Points: 
  • (NASDAQ: MYGN), a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study of nearly 21,000 patients that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight® Psychotropic test .
  • “We are encouraged by the initial results of this study that showed how the proportion of patients with hospitalizations was significantly reduced after GeneSight testing,” said Dale Muzzey, chief scientific officer, Myriad Genetics.
  • We expect to share additional study results later this year.”
    The study demonstrated that the percentage of patients with hospitalizations was significantly reduced 180 days after GeneSight testing:
    39% relative reduction in psychiatric-related hospitalizations.
  • Significant reduction in hospitalizations for patients who were switched to a medication with no or moderate gene-drug interactions.

Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Retrieved on: 
星期五, 三月 22, 2024
MYGN, Diagnosis, Genetic testing, Patent, Combinatorics, Genetics, Patient, Neoplasm, Research, DNA, Myriad Genetics, Doctor of Philosophy, Oncology, Medicine, University, MD Anderson Cancer Center, MRD, Intellectual property, FDA, Estate (law), Pharmaceutical industry

U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s foundational and proprietary method of preparing cell free DNA.

Key Points: 
  • U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s foundational and proprietary method of preparing cell free DNA.
  • This method describes a key aspect of tumor-informed MRD assays that detect circulating tumor DNA (ctDNA) through sequencing.
  • Specifically, the patented method relates to the manner in which a sample is sufficiently enriched with ctDNA that it can be detected, if present, with high sensitivity and specificity.
  • “The 2016 filing date of this patent—at the advent of MRD development—highlights Myriad’s foresight about the potential role of tumor-derived cell-free DNA in the expanding field of cancer diagnostics,” said Paul J. Diaz, President and CEO, Myriad Genetics.

Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device

Retrieved on: 
星期三, 三月 20, 2024
MYGN, PCR, Arm, Genetic testing, Patent, Risk, Genetics, DNA, Snap, Myriad Genetics, Doctor of Philosophy, Medicine, Male, Pharmaceutical industry

11,932,907, titled Fetal Sex Determination Using Capillary Blood From Upper Arm, provides protection for Myriad’s SneakPeek Snap® products in the U.S through 2040.

Key Points: 
  • 11,932,907, titled Fetal Sex Determination Using Capillary Blood From Upper Arm, provides protection for Myriad’s SneakPeek Snap® products in the U.S through 2040.
  • Consumers place the Snap device on their arm, press the button, and the sample is collected in one to four minutes.
  • “We view this patent grant as recognition of our innovative approach to fetal sex testing using PCR-based techniques with any push-button blood collection device,” stated Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics.
  • “This patent grant promotes SneakPeek Snap exclusivity in the US market through at least 2040 and provides an opportunity for licensing agreements with leading push-button blood collection device suppliers, positioning us as a strategic partner.”